Circulating adiponectin levels in various malignancies: An updated meta-analysis of 107 studies

Oncotarget

Volumn 7, Issue 30, 2016, Pages 48671-48691

  Wei, Tai ^a   Ye, Peng ^a   Peng, Xin ^a   Wu, Li Ling ^b   Yu, Guang Yan ^a  

^a PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Adiponectin; Biomarker; Diagnosis; Malignancy; Meta analysis

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN; TUMOR MARKER;

ACUTE LEUKEMIA; BREAST CANCER; CARCINOGENESIS; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; EARLY DIAGNOSIS; ENDOMETRIUM CARCINOMA; ESOPHAGUS CANCER; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LINEAR REGRESSION ANALYSIS; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SENSITIVITY ANALYSIS; STOMACH CANCER; THYROID CANCER; BLOOD; DEFICIENCY; EARLY CANCER DIAGNOSIS; INBORN ERROR OF METABOLISM; META ANALYSIS; METABOLISM; NEOPLASM; PROCEDURES; RISK FACTOR;

ADIPONECTIN; BIOMARKERS, TUMOR; CARCINOGENESIS; EARLY DETECTION OF CANCER; HUMANS; METABOLISM, INBORN ERRORS; NEOPLASMS; RISK FACTORS;

EID: 84982860540     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8932     Document Type: Review

References (133)

1. Bray F, Ren JS, Masuyer E and Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008 Int J Cancer. 2013; 132:1133-1145.
2. Kelly T, Yang W, Chen CS, Reynolds K and He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008; 32:1431-1437.
3. Calle EE and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4:579-591.
4. Trevellin E, Scarpa M, Carraro A, Lunardi F, Kotsafti A, Porzionato A, Saadeh L, Cagol M, Alfieri R, Tedeschi U, Calabrese F, Castoro C and Vettor R. Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion. Oncotarget. 2015; 6:11203-11215. doi: 10.18632/oncotarget.3587.
5. Scherer PE, Williams S, Fogliano M, Baldini G and Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995; 270:26746-26749.
6. Hu E, Liang P and Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996; 271:10697-10703.
7. Fujimatsu D, Kotooka N, Inoue T, Nishiyama M and Node K. Association between high molecular weight adiponectin levels and metabolic parameters. J Atheroscler Thromb. 2009; 16:553-559.
8. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423:762-769.
9. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS and Lodish HF. T-cadherin is a receptor for hexameric and highmolecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA. 2004; 101:10308-10313.
10. Ye R and Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab. 2013; 2:133-141.
11. Liu YM, Lacorte JM, Viguerie N, Poitou C, Pelloux V, Guy-Grand B, Coussieu C, Langin D, Basdevant A and Clement K. Adiponectin gene expression in subcutaneous adipose tissue of obese women in response to short-term very low calorie diet and refeeding. J Clin Endocrinol Metab. 2003; 88:5881-5886.
12. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y and Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003; 9:5699-5704.
13. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S and Bedir S. Prostate cancer and adiponectin. Urology. 2005; 65:1168-1172.
14. Gu C, Qu Y, Zhang G, Sun L, Zhu Y and Ye D. A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer. Oncotarget. 2015; 6:32205-32211. doi: 10.18632/oncotarget.4980.
15. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM and Lu KH. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006; 106:2376-2381.
16. Fukumoto J, Otake T, Tajima O, Tabata S, Abe H, Mizoue T, Ohnaka K and Kono S. Adiponectin and colorectal adenomas: self defense forces health study. Cancer Sci. 2008; 99:781-786.
17. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y and Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006; 345:271-279.
18. Zhang L, Wen K, Han X, Liu R and Qu Q. Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway. Gynecol Oncol. 2015; 137:311-320.
19. Pezzilli R, Barassi A, Corsi MM, Morselli-Labate AM, Campana D, Casadei R, Santini D, Corinaldesi R and D'Eril GM. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scand J Gastroenterol. 2010; 45:93-99.
20. Chen MJ, Yeh YT, Lee KT, Tsai CJ, Lee HH and Wang SN. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol. 2012; 106:181-187.
21. Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, Diakopoulos KN, Kyttaris V, Panagiotou V, Mylvaganam G, Tseleni-Balafouta S and Mantzoros CS. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab. 2011; 96:E2023-2028.
22. Spyridopoulos TN, Dessypris N, Antoniadis AG, Gialamas S, Antonopoulos CN, Katsifoti K, Adami HO, Chrousos GP and Petridou ET. Insulin resistance and risk of renal cell cancer: a case-control study. Hormones (Athens). 2012; 11:308-315.
23. Liao LM, Weinstein SJ, Pollak M, Li Z, Virtamo J, Albanes D, Chow WH and Purdue MP. Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis. 2013; 34:109-112.
24. Liao LM, Schwartz K, Pollak M, Graubard BI, Li Z, Ruterbusch J, Rothman N, Davis F, Wacholder S, Colt J, Chow WH and Purdue MP. Serum leptin and adiponectin levels and risk of renal cell carcinoma. Obesity (Silver Spring). 2013; 21:1478-1485.
25. Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK and Trichopoulos D. Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer. 2006; 94:156-160.
26. Moschovi M, Trimis G, Vounatsou M, Katsibardi K, Margeli A, Damianos A, Chrousos G and Papassotiriou I. Serial plasma concentrations of adiponectin, leptin, and resistin during therapy in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010; 32:e8-13.
27. Aref S, Ibrahim L, Azmy E and Al Ashary R. Impact of serum adiponectin and leptin levels in acute leukemia. Hematology. 2013; 18:198-203.
28. Petridou ET, Dessypris N, Panagopoulou P, Sergentanis TN, Mentis AF, Pourtsidis A, Polychronopoulou S, Kalmanti M, Athanasiadou-Piperopoulou F and Moschovi M. Adipocytokines in relation to Hodgkin lymphoma in children. Pediatr Blood Cancer. 2010; 54:311-315.
29. Pamuk GE, Turgut B, Demir M and Vural O. Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome. J Exp Clin Cancer Res. 2006; 25:537-541.
30. Petridou ET, Sergentanis TN, Dessypris N, Vlachantoni IT, Tseleni-Balafouta S, Pourtsidis A, Moschovi M, Polychronopoulou S, Athanasiadou-Piperopoulou F, Kalmanti M and Mantzoros CS. Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study. J Clin Oncol. 2009; 27:5049-5055.
31. Conroy SM, Maskarinec G, Morimoto Y, Franke AA, Cooney RV, Wilkens LR, Goodman MT, Hernadez BY, Le Marchand L, Henderson BE and Kolonel LN. Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2013; 22:337-347.
32. Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C, Lekka A and Mantzoros CS. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control. 2009; 20:193-199.
33. Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N and Purdue MP. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood. 2012; 120:4418-4420.
34. Antoniadis AG, Petridou ET, Antonopoulos CN, Dessypris N, Panagopoulou P, Chamberland JP, Adami HO, Gogas H and Mantzoros CS. Insulin resistance in relation to melanoma risk. Melanoma Res. 2011; 21:541-546.
35. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, Higgins B, Lokshin A, Troyer D, Hernandez J, Lynch S, Leach RJ and Thompson IM. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev. 2006; 15:1331-1335.
36. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A and Mantzoros CS. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev. 2007; 16:308-313.
37. Housa D, Vernerova Z, Heracek J, Prochazka B, Cechak P, Kuncova J and Haluzik M. Adiponectin as a potential marker of prostate cancer progression: studies in organconfined and locally advanced prostate cancer. Physiol Res. 2008; 57:451-458.
38. Grosman H, Fabre B, Mesch V, Lopez MA, Schreier L, Mazza O and Berg G. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer. Aging Male. 2010; 13:87-92.
39. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T and Ma J. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010; 56:34-43.
40. Al Khaldi RM, Al Mulla F, Al Awadhi S, Kapila K and Mojiminiyi OA. Associations of single nucleotide polymorphisms in the adiponectin gene with adiponectin levels and cardio-metabolic risk factors in patients with cancer. Dis Markers. 2011; 30:197-212.
41. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ and Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20:2618-2627.
42. Lopez Fontana CM, Maselli ME, Perez Elizalde RF, Di Milta Monaco NA, Uvilla Recupero AL and Lopez Laur JD. Leptin increases prostate cancer aggressiveness. J Physiol Biochem. 2011; 67:531-538.
43. Tewari R, Rajender S, Natu SM, Goel A, Dalela D, Goel MM and Tondon P. Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men-a cross-sectional study. Cytokine. 2013; 63:130-134.
44. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, Mejean C, Latino-Martel P, Hercberg S, Galan P and Czernichow S. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol. 2013; 177:3-13.
45. Chang MC, Chang YT, Su TC, Yang WS, Chen CL, Tien YW, Liang PC, Wei SC and Wong JM. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas. 2007; 35:16-21.
46. Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J and Albanes D. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol. 2008; 168:1047-1055.
47. Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, Karmaniolas K, Pelecanos N, Tseleni-Balafouta S, Dionyssiou-Asteriou A and Mantzoros CS. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009; 20:625-633.
48. Krechler T, Zeman M, Vecka M, Macasek J, Jachymova M, Zima T and Zak A. Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma. 2011; 58:58-64.
49. Grote VA, Rohrmann S, Dossus L, Nieters A, Halkjaer J, Tjonneland A, Overvad K, Stegger J, Chabbert-Buffet N, Boutron-Ruault MC, Clavel-Chapelon F, Teucher B, Becker S, Montonen J, Boeing H, Trichopoulou A, et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int J Cancer. 2012; 130:2428-2437.
50. Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, Rifai N, Pollak MN, Cochrane BB, Kaklamani V, Lin JH, Manson JE, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013; 105:95-103.
51. Jamieson NB, Brown DJ, Michael Wallace A and McMillan DC. Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine. 2004; 27:90-92.
52. Petridou ET, Mitsiades N, Gialamas S, Angelopoulos M, Skalkidou A, Dessypris N, Hsi A, Lazaris N, Polyzos A, Syrigos C, Brennan AM, Tseleni-Balafouta S and Mantzoros CS. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology. 2007; 73:261-269.
53. Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkantonis I, Gratsias I and Syrigos KN. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer. 2008; 61:391-397.
54. Gulen ST, Karadag F, Karul AB, Kilicarslan N, Ceylan E, Kuman NK and Cildag O. Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung. 2012; 190:327-332.
55. Kerenidi T, Lada M, Tsaroucha A, Georgoulias P, Mystridou P and Gourgoulianis KI. Clinical significance of serum adipokines levels in lung cancer. Med Oncol. 2013; 30:507.
56. Kotani K, Wakai K, Shibata A, Fujita Y, Ogimoto I, Naito M, Kurozawa Y, Suzuki H, Yoshimura T and Tamakoshi A. Serum adiponectin multimer complexes and liver cancer risk in a large cohort study in Japan. Asian Pac J Cancer Prev. 2009; 10 Suppl:87-90.
57. Liu CJ, Chen PJ, Lai MY, Liu CH, Chen CL, Kao JH and Chen DS. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol Int. 2009; 3:364-370.
58. Sumie S, Kawaguchi T, Kuromatsu R, Takata A, Nakano M, Satani M, Yamada S, Niizeki T, Torimura T and Sata M. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS One. 2011; 6:e26840.
59. Khattab MA, Eslam M, Mousa YI, Ela-Adawy N, Fathy S, Shatat M, Abd-Aalhalim H, Kamal A and Sharawe MA. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann Hepatol. 2012; 11:487-494.
60. Sadik NA, Ahmed A and Ahmed S. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum Exp Toxicol. 2012; 31:311-321.
61. Chen CL, Yang WS, Yang HI, Chen CF, You SL, Wang LY, Lu SN, Liu CJ, Kao JH, Chen PJ, Chen DS and Chen CJ. Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in taiwan. Cancer Epidemiol Biomarkers Prev. 2014; 23:1659-1671.
62. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K and Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005; 11:466-472.
63. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, Kato K, Hamaguchi T and Shimada Y. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 2009; 44:685-690.
64. Seker M, Bilici A, Sonmez B, Ustaalioglu BB, Gumus M, Gozu H, Sargin M, Orcun A, Gezen C, Eser M, Bildik N and Salepci T. The association of serum adiponectin levels with histopathological variables in gastric cancer patients. Med Oncol. 2010; 27:1319-1323.
65. Diakowska D, Markocka-Maczka K, Szelachowski P and Grabowski K. Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients. Dis Markers. 2014; 2014:619649.
66. Diao Y, Li H, Li H, Zhou Y, Ma Q, Wang Y and Li D. Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma. Lipids Health Dis. 2009; 8:48.
67. Yildirim A, Bilici M, Cayir K, Yanmaz V, Yildirim S and Tekin SB. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol. 2009; 39:92-96.
68. Nakajima TE, Yamada Y, Hamano T, Furuta K, Oda I, Kato H, Kato K, Hamaguchi T and Shimada Y. Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol. 2010; 136:261-266.
69. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, Rinaldi S, Dossus L, Slimani N, Lundin E, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Mesrine S, Joulin V, et al. Plasma adiponectin levels and endometrial cancer risk in pre-and postmenopausal women. J Clin Endocrinol Metab. 2007; 92:255-263.
70. Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K and Tanaka K. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol. 2010; 119:65-69.
71. Friedenreich CM, Langley AR, Speidel TP, Lau DC, Courneya KS, Csizmadi I, Magliocco AM, Yasui Y and Cook LS. Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr Relat Cancer. 2012; 19:785-792.
72. Dallal CM, Brinton LA, Bauer DC, Buist DS, Cauley JA, Hue TF, Lacroix A, Tice JA, Chia VM, Falk R, Pfeiffer R, Pollak M, Veenstra TD, Xu X and Lacey JV, Jr. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. Endocr Relat Cancer. 2013; 20:151-160.
73. Dossus L, Lukanova A, Rinaldi S, Allen N, Cust AE, Becker S, Tjonneland A, Hansen L, Overvad K, Chabbert-Buffet N, Mesrine S, Clavel-Chapelon F, Teucher B, Chang-Claude J, Boeing H, Drogan D, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort-a factor analysis. Am J Epidemiol. 2013; 177:787-799.
74. Erdogan S, Sezer S, Baser E, Gun-Eryilmaz O, Gungor T, Uysal S and Yilmaz FM. Evaluating vaspin and adiponectin in postmenopausal women with endometrial cancer. Endocr Relat Cancer. 2013; 20:669-675.
75. Luhn P, Dallal CM, Weiss JM, Black A, Huang WY, Lacey JV, Jr., Hayes RB, Stanczyk FZ, Wentzensen N and Brinton LA. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2013; 22:1304-1312.
76. Ma Y, Liu Z, Zhang Y and Lu B. Serum leptin, adiponectin and endometrial cancer risk in Chinese women. J Gynecol Oncol. 2013; 24:336-341.
77. Mihu D, Ciortea R and Mihu CM. Abdominal adiposity through adipocyte secretion products, a risk factor for endometrial cancer. Gynecol Endocrinol. 2013; 29:448-451.
78. Ohbuchi Y, Suzuki Y, Hatakeyama I, Nakao Y, Fujito A, Iwasaka T and Isaka K. A lower serum level of middle-molecular-weight adiponectin is a risk factor for endometrial cancer. Int J Clin Oncol. 2014; 19:667-673.
79. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G and Trichopoulos D. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004; 89:1102-1107.
80. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, Chen HY, Hou MF and Yuan SS. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006; 237:109-114.
81. Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL, Sun Y, Wu Q and Chen L. Adipocytokines and breast cancer risk. Chin Med J (Engl). 2007; 120:1592-1596.
82. Kang JH, Yu BY and Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci. 2007; 22:117-121.
83. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W and Mantzoros CS. Total and highmolecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2007; 92:1041-1048.
84. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS and Hankinson SE. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007; 92:1510-1516.
85. Cust AE, Stocks T, Lukanova A, Lundin E, Hallmans G, Kaaks R, Jonsson H and Stattin P. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat. 2009; 113:567-576.
86. Hancke K, Grubeck D, Hauser N, Kreienberg R and Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat. 2010; 119:367-367.
87. Shahar S, Salleh RM, Ghazali AR, Koon PB and Mohamud WN. Roles of adiposity, lifetime physical activity and serum adiponectin in occurrence of breast cancer among Malaysian women in Klang Valley. Asian Pac J Cancer Prev. 2010; 11:61-66.
88. Dalamaga M, Karmaniolas K, Papadavid E, Pelekanos N, Sotiropoulos G and Lekka A. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. Menopause. 2011; 18:1198-1204.
89. Al Awadhi SA, Al Khaldi RM, Al Rammah T, Kapila K and Mojiminiyi OA. Associations of adipokines & insulin resistance with sex steroids in patients with breast cancer. Indian J Med Res. 2012; 135:500-505.
90. Gulcelik MA, Colakoglu K, Dincer H, Dogan L, Yenidogan E and Gulcelik NE. Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev. 2012; 13:395-398.
91. Alokail MS, Al-Daghri N, Abdulkareem A, Draz HM, Yakout SM, Alnaami AM, Sabico S, Alenad AM and Chrousos GP. Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk? BMC Cancer. 2013; 13:54.
92. Gross AL, Newschaffer CJ, Hoffman-Bolton J, Rifai N and Visvanathan K. Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013; 22:1319-1324.
93. Ollberding NJ, Kim Y, Shvetsov YB, Wilkens LR, Franke AA, Cooney RV, Maskarinec G, Hernandez BY, Henderson BE, Le Marchand L, Kolonel LN and Goodman MT. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res (Phila). 2013; 6:188-195.
94. Minatoya M, Kutomi G, Shima H, Asakura S, Otokozawa S, Ohnishi H, Akasaka H, Miura T, Mori M and Hirata K. Relation of serum adiponectin levels and obesity with breast cancer: a Japanese case-control study. Asian Pac J Cancer Prev. 2014; 15:8325-8330.
95. Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, Saito T, Togashi H, Nakamura T, Matsuzawa Y and Kawata S. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res. 2005; 11:3642-3646.
96. Wei EK, Giovannucci E, Fuchs CS, Willett WC and Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005; 97:1688-1694.
97. Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G, Kaaks R and Stattin P. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond). 2008; 32:304-314.
98. Erarslan E, Turkay C, Koktener A, Koca C, Uz B and Bavbek N. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci. 2009; 54:862-868.
99. Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R and Ferroni P. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res. 2009; 29:3321-3327.
100. Kumor A, Daniel P, Pietruczuk M and Malecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2009; 24:275-281.
101. Gonullu G, Kahraman H, Bedir A, Bektas A and Yucel I. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis. 2010; 25:205-212.
102. Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S, Dulger AC, Demiriz B and Tuzun S. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol. 2010; 8:85.
103. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T and Shimada Y. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010; 101:1286-1291.
104. Otake S, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, Sasaki Y, Nishise S and Kawata S. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol. 2010; 16:1252-1257.
105. Yamaji T, Iwasaki M, Sasazuki S and Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res. 2010; 70:5430-5437.
106. Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Silva C, Rotellar F, Hernandez-Lizoain JL, Baixauli J, Valenti V, Pardo F, Salvador J and Fruhbeck G. Upregulation of the novel proinflammatory adipokines lipocalin-2, chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J Nutr Biochem. 2011; 22:634-641.
107. Aleksandrova K, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duijnhoven FJ, Fedirko V, Rinaldi S, Romieu I, Riboli E, Romaguera D, Westphal S, Overvad K, Tjonneland A, Boutron-Ruault MC, Clavel-Chapelon F, et al. Total and high-molecular weight adiponectin and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Carcinogenesis. 2012; 33:1211-1218.
108. Chen MW, Ye S, Zhao LL, Wang SY, Li YX, Yu CJ, Xie HJ and Wang YM. Association of plasma total and highmolecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol. 2012; 29:3129-3135.
109. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, Mejean C, Latino-Martel P, Hercberg S, Galan P and Czernichow S. Pre-diagnostic levels of adiponectin and soluble vascular cell adhesion molecule-1 are associated with colorectal cancer risk. World J Gastroenterol. 2012; 18:2805-2812.
110. Danese E, Minicozzi AM, Montagnana M, De Manzoni G, Lippi G and Guidi GC. Lack of an association between circulating adiponectin levels and risk of colorectal adenoma. Clin Lab. 2013; 59:211-214.
111. Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci EL and Chan AT. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res (Phila). 2013; 6:875-885.
112. Guo XH, Wang JY, Gao Y, Gao M, Yu GY, Xiang RL, Li L, Yang NY, Cong X, Xu XY, Li SL, Peng X and Wu LL. Decreased adiponectin level is associated with aggressive phenotype of tongue squamous cell carcinoma. Cancer Sci. 2013; 104:206-213.
113. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, Inukai T, Okuno T and Node K. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol. 2007; 100:569-574.
114. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R and Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006; 29:1357-1362.
115. Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, Mao C, Wang D, Chen J and Yuan G. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014; 23:158-165.
116. An W, Bai Y, Deng SX, Gao J, Ben QW, Cai QC, Zhang HG and Li ZS. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev. 2012; 21:126-133.
117. Ferroni P, Palmirotta R, Spila A, Martini F, Raparelli V, Fossile E, Mariotti S, Del Monte G, Buonomo O, Roselli M and Guadagni F. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res. 2007; 27:483-489.
118. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8:731-737.
119. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J and Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003; 301:1045-1050.
120. Bauche IB, Ait El Mkadem S, Rezsohazy R, Funahashi T, Maeda N, Miranda LM and Brichard SM. Adiponectin downregulates its own production and the expression of its AdipoR2 receptor in transgenic mice. Biochem Biophys Res Commun. 2006; 345:1414-1424.
121. Qi L, Rimm E, Liu S, Rifai N and Hu FB. Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care. 2005; 28:1022-1028.
122. Tietge UJ, Boker KH, Manns MP and Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab. 2004; 287:E82-89.
123. Barresi V, Grosso M, Giuffre G, Tuccari G and Barresi G. The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clinical Pathol. 2009; 62:705-709.
124. Yabushita H, Iwasaki K, Obayashi Y and Wakatsuki A. Clinicopathological roles of adiponectin and leptin receptors in endometrial carcinoma. Oncol Lett. 2014; 7:1109-1117.
125. Abdul-Ghafar J, Oh SS, Park SM, Wairagu P, Lee SN, Jeong Y, Eom M, Yong SJ and Jung SH. Expression of adiponectin receptor 1 is indicative of favorable prognosis in non-small cell lung carcinoma. Tohoku J Exp Med. 2013; 229:153-162.
126. Otvos L, Jr., Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J and Surmacz E. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 2011; 11:90.
127. Liu J, Xu A, Lam KS, Wong NS, Chen J, Shepherd PR and Wang Y. Cholesterol-induced mammary tumorigenesis is enhanced by adiponectin deficiency: role of LDL receptor upregulation. Oncotarget. 2013; 4:1804-1818. doi: 10.18632/oncotarget.1364.
128. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ and Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005; 18:283-293.
129. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ and Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005; 18:283-293.
130. Lee HP, Lin CY, Shih JS, Fong YC, Wang SW, Li TM and Tang CH. Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-alpha pathway. Oncotarget. 2015; 6:36746-36761. doi: 10.18632/oncotarget.5479.
131. Huang B, Cheng X, Wang D, Peng M, Xue Z, Da Y, Zhang N, Yao Z, Li M, Xu A and Zhang R. Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1alpha signaling. Oncotarget. 2014; 5:4732-4745. doi: 10.18632/oncotarget.1963.
132. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000; 283:2008-2012.
133. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603-605.